- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 948KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 794KB)
Amivantamab – November 2024
Amivantamab; Solution concentrate for I.V. infusion 350 mg in 7 mL; Rybrevant®
Last updated
30 May 2025